10x Genomics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by 10x Genomics, Inc. on February 12, 2026. The filing serves to announce the Company's financial results for the fourth quarter and full year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, management commentary, risk factors, or details on unusual items. The document explicitly states that the information furnished pursuant to Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 12, 2026) for actual Q4 and full-year 2025 financial figures.
- Verify specific revenue growth rates and profitability metrics against prior periods in the press release.
- Check for any updated forward-looking guidance or outlook statements in the attached exhibit.
- Confirm the status of the Company's emerging growth company election, as indicated by the unchecked boxes in the filing.